Cancer biomarkers for hepatocellular carcinomas: From traditional markers to recent topics

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 6, 2011, Pages 959-966

  Masuda, Tomomi ^a   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

glycosylation; HCC; tumor markers

Indexed keywords

ALPHA FETOPROTEIN; AUTOANTIBODY; DCP PROTEIN; DECARBOXYPROTHROMBIN; FUCOSYLATED ALPHA FETOPROTEIN; GLYCOPROTEIN GP73; GLYCOPROTEIN GPP130; GLYPICAN 3; HEAT SHOCK PROTEIN 70; PROTHROMBIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ASCITES; BRAIN DISEASE; CANCER MORTALITY; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; END STAGE LIVER DISEASE; GLYCOBIOLOGY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; METABOLIC DISORDER; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; VIRUS CARRIER; VIRUS INFECTION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958258019     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.152     Document Type: Review

References (89)

1. Tateishi R, Yoshida H, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008;2:17-30. (Pubitemid 351250400)
2. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143:725-9. (Pubitemid 351918934)
3. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 Version 2.0. Lyon, France: IARC Press; 2004.
4. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:27-34.
5. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
7. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010;52:252-7.
8. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22: 5093-107. (Pubitemid 37059591)
9. El Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62-5. (Pubitemid 32016888)
10. Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, et al. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2004;49:850-3. (Pubitemid 38870213)
11. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2006;22:248-53. (Pubitemid 44090061)
12. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752-63. (Pubitemid 351615415)
13. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2001;34: 1225-41. (Pubitemid 33096596)
14. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001; 120:1828-53.
15. Vullierme MP, Paradis V, Chirica M, Castaing D, Belghiti J, Soubrane O, et al. Hepatocellular carcinoma-what's new? J Visc Surg 2010;147:1-12.
16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepa-tol 2001;35:421-30. (Pubitemid 32844200)
17. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnù L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-44. (Pubitemid 34245906)
18. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepa-tocellular carcinoma. Gastroenterology 2010;138:493-502.
19. Mendizabal M, Reddy KR. Current management of hepatocel-lular carcinoma. Med Clin North Am 2009;93:885-900.
20. Tatarinov YS. Detection of embryospecific alpha-globulin in the blood sera of patients with primary liver tumour. Vopr Med Khim 1964;10:90-1.
21. Koteish A, Thuluvath PJ. Screening for hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S185-90.
22. McLeod JF, Cooke NE. The vitamin D-binding protein, alpha-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. J Biol Chem 1989;264:21760-9. (Pubitemid 20028745)
23. Chan DW, Sell S. Tumour markers. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 2nd ed. W.B. Philadelphia: Saunders Company; 1994;897-927.
24. Ruoslahti E, Seppala M. Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for alpha-fetoprotein. Demonstration of alpha-fetoprotein in serum of healthy human adults. Int J Cancer 1971;8:374-83.
25. Deutsch HF. Chemistry and biology of alpha-fetoprotein. Adv Cancer Res 1991;56:253-312.
26. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp BiolMed (Maywood) 2001;226:377-408. (Pubitemid 32506364)
27. O'Neill G, Tsega E, Gold P, Murgita RA. Regulation of human lymphocyte activation by alpha-fetoprotein. Evidence for selective suppression of Ia-associated T-cell proliferation in vitro. Oncodev Biol Med 1982;3:135-50. (Pubitemid 12036397)
28. Aoyagi Y. Carbohydrate-based measurements on alpha-fetopro-tein in the early diagnosis of hepatocellular carcinoma. Gly-coconj J 1995;12:194-9.
29. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrom-bin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
30. Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Naka-nishi Y, et al. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005;280:6409-15. (Pubitemid 40341187)
31. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31. (Pubitemid 14101298)
32. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-9. (Pubitemid 32105702)
33. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006; 41:1214-9. (Pubitemid 46487212)
34. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994;73:2464-71. (Pubitemid 24155520)
35. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yama-moto M, et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-car-boxy prothrombin alone. J Gastroenterol Hepatol 2001;16: 1290-6. (Pubitemid 34088278)
36. Hamamura K, Shiratori Y, Shiina S, Imamura M, Obi S, Sato S, et al. Unique clinical characteristics of patients with hepa-tocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000;88:1557-64. (Pubitemid 30183140)
37. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisa-naga Y, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006;4:111-7. (Pubitemid 43129532)
38. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fon-tana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from non-malignant chronic liver disease in American patients. Hepatology 2003;37:1114-21. (Pubitemid 36538688)
39. Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Mat-suo N, et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007;282:8741-8. (Pubitemid 47093522)
40. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fuco-sylated glycoproteins in the development of primary hepato-cellular carcinoma. J Proteome Res 2006;6:308-15. (Pubitemid 43224256)
41. Breborowicz J, Mackiewicz A, Breborowicz D. Microhetero-geneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol 1981;14: 15-20. (Pubitemid 11056257)
42. Taketa K, Izumi M, Ichikawa E. Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins. Ann N Y Acad Sci 1983;417:61-8. (Pubitemid 14187627)
43. Uozumi N, Yanagidani S, Miyoshi E, Ihara Y, Sakuma T, Gao CX, et al. Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D- glucosaminide alpha1-)6fuco-syltransferase. J Biol Chem 1996;271:27810-7. (Pubitemid 26367356)
44. Yanagidani S, Uozumi N, Ihara Y, Miyoshi E, Yamaguchi N, Taniguchi N. Purification and cDNA cloning of GDP-L-Fuc:N-acetyl-beta-D-glucosaminide:alpha1- 6 fucosyltransferase (alpha1-6 FucT) from human gastric cancer MKN45 cells. J Biochem 1997;121:626-32. (Pubitemid 27145920)
45. Noda K, Miyoshi E, Gu J, Gao CX, Nakahara S, Kitada T, et al. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res 2003;63:6282-9. (Pubitemid 37255175)
46. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of lens culinaris agglutinin A-reactive alpha-feto-protein in small hepatocellular carcinomas. Gastroenterology 1996;111:996-1001. (Pubitemid 26327602)
47. Cheng HT, Chang YH, Chen YY, Lee TH, Tai DI, Lin DY. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. J Chin Med Assoc 2007;70:310-7.
48. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 2006;281:2572-7. (Pubitemid 43845717)
49. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797-806. (Pubitemid 44536989)
50. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepato-cellular carcinoma in the United States. Dig Dis Sci 2007;52: 776-82.
51. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and non-viral liver disease. Hepatology 2002;35:1431-40. (Pubitemid 34966897)
52. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. GP73, a novel Golgi-localized protein upre-gulated by viral infection. Gene 2000;249:53-65. (Pubitemid 30300752)
53. Puri S, Bachert C, Fimmel CJ, Linstedt AD. Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic 2002;3:641-53.
54. Norton PA, Comunale MA, Krakover J, Rodemich L, Pirog N, D'Amelio A, et al. N-Linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem 2008;104:136-49.
55. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in wood-chucks and humans. Proc Natl Acad Sci USA 2005;102: 779-84. (Pubitemid 40282742)
56. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 2007;8: 1415-23. (Pubitemid 47394245)
57. Hutchinson WL, Du MQ, Johnson PJ, Williams R. Fucosyl-transferases: differential plasma and tissue alterations in hepa-tocellular carcinoma and cirrhosis. Hepatology 1991;13:683-8.
58. Yanagi M, Aoyagi Y, Suda T, Mita Y, Asakura H. N-acetylglu- cosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:1282-9. (Pubitemid 34088277)
59. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001;108:497-501. (Pubitemid 32777726)
60. Filmus J, Church JG, Buick RN. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol 1988;8:4243-9.
61. Li M, Choo B, Wong ZM, Filmus J, Buick RN. Expression of OCI-5/glypican3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res 1997; 235:3-12. (Pubitemid 27381675)
62. Farooq M, Hwang SY, Park MK, Kim JC, Kim MK, Sung YK. Blocking endogenous glypican-3 expression releases Hep 3B from G1 arrest. Mol Cells 2003;15:356-60.
63. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyos-hi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. (Pubitemid 36799110)
64. Neri G, Gurrieri F, Zanni G, Lin A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79:279-83. (Pubitemid 28447109)
65. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, et al. Enhanced glypica-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-64. (Pubitemid 32234802)
66. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepa-tocellular carcinoma. Cancer Res 2004;64:2418-23. (Pubitemid 38523895)
67. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, et al. Glypican-3, overexpressed in hepatocel-lular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-65. (Pubitemid 36020219)
68. Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003;94:259-62. (Pubitemid 36575892)
69. Lu ZL, Luo DZ, Wen JM. Expression and significance of tumor-related genes in HCC. World J Gastroenterol 2005;11: 3850-4.
70. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009;34:649-56.
71. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 in hepatocellular carcinoma. J Korean Med Sci 2005;20:829-34. (Pubitemid 41587241)
72. Saluja A, Dudeja V. Heat shock proteins in pancreatic diseases. J Gastroenterol Hepatol 2008;23(Suppl 1):42-5.
73. Atkins D, Lichtenfels R, Seliger B. Heat shock proteins in renal cell carcinomas. Contrib Nephrol 2005;148:35-56. (Pubitemid 43264921)
74. Yin Y, Qin Q, Zhang W, Zhao J, Zhang C, Yu J. Overexpression of heat shock protein 70 and spontaneous cancer cell apoptosis in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2001;9:84-5.
75. Kingston RE, Baldwin AS, Sharp PA. Regulation of heat shock protein 70 gene expression by c-myc. Nature 1984;312:280-2. (Pubitemid 15202006)
76. Konno A, Sato N, Yagihashi A, Torigoe T, Cho J, Torimoto K, et al. Heat or stress-inducible transformation-associated cell-stress antigen on the activated H-ras-oncogene-transfected rat fibroblast. Cancer Res 1989;49:6578-82. (Pubitemid 20008790)
77. Pinashi-Kimmhi O, Michalowitz D, Ben-Zeev A, Oren M. Specific interaction between the p53 cellular tumor antigen and major heat shock proteins. Nature 1986;320:182-5.
78. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcino-genesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207. (Pubitemid 36042161)
79. Sakamoto M. Early HCC: diagnosis and molecular markers. J Gastroenterol 2009;44(Suppl 19):108-11.
80. Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, Zhang JY. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 2008;7:4004-12.
81. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Harada T, Fujimoto M, et al. Proteomic analyses of autoantibodies in patients with hepatocellular carcinoma. Proteomics 2006;6: 3894-900. (Pubitemid 44065166)
82. Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibro-genesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int 2008; 28:1052-64.
83. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J 2009;85:44-54.
84. Mas VR, Fisher RA, Archer KJ, Maluf DG. Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics 2009;6:421-31.
85. Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol 2009;15:2433-40.
86. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R, et al. Non-invasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein gly-comics. Nat Med 2004;10:429-34. (Pubitemid 38508524)
87. Rockey DC, Bissell DM. Non-invasive measures of liver fibro-sis. Hepatology 2006;43:113-20.
88. Ressom HW, Varghese RS, Goldman L, An Y, Loffredo CA, Abdel-Hamid M, et al. Analysis of MALDI-TOF mass spec-trometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res 2008;7:603-10. (Pubitemid 351294022)
89. Tang Z, Varghese RS, Bekesova S, Loffredo CA, Hamid MA, Kyselova Z, et al. Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectro-metry data. J Proteome Res 2010;9:104-12.